Moleculin Biotech, Inc. MBRX 深 沪
已收盘 02-06 16:00:00 美东时间
4.31
+0.400
+10.23%
华盛通- 最 高4.3884
- 今 开4.16
- 成交量 15.83万股
- 最 低 3.85
- 昨 收 3.91
- 总市值 1327.15万
- 52周最高 55.50
- 市盈率 静 --
- 换手率 5.14%
- 52周最低 3.13
- 委 比 0.00%
- 总股本 307.92万
- 历史最高 21555.00
- 量 比 2.06
- 振 幅 13.77%
- 历史最低 3.25
- 每 手 1
- 风险率 8.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Biotech Shareholders Approve Warrant Share Issuance
Moleculin Biotech ( ($MBRX) ) has issued an announcement. At a special meeting ...
02-06 01:17
Moleculin Biotech Inc. hielt Hauptversammlung ab
Moleculin Biotech Inc. hielt Hauptversammlung ab Moleculin Biotech Inc. hat am 5. Februar 2026 eine außerordentliche Hauptversammlung abgehalten. Die Aktionäre haben der Ausgabe von bis zu 2.610.823 Stammaktien im Zusammenhang mit bestimmten Warrants zugestimmt. Der vorgeschlagenen Namensänderung vo
02-06 00:55
Moleculin Biotech Inc. Held Special Stockholder Meeting
Moleculin Biotech Inc. Held Special Stockholder Meeting Moleculin Biotech Inc. held a Special Meeting of Stockholders on February 5, 2026. Stockholders approved the issuance of up to 2,610,823 shares of common stock upon the exercise of certain warrants issued on December 11, 2025. A proposal to ame
02-06 00:55
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Biotech provided an update on its drug candidates Annamycin and WP1066. Annamycin is advancing in its pivotal Phase 2B/3 MIRACLE trial for second-line acute myeloid leukemia (AML), with expected milestones including data readouts, global expansion across nine countries, and the potential launch of a pancreatic cancer trial. WP1066, targeting brain tumors, is in a Phase 2 trial at Northwestern University and plans to begin a pediatric tr...
01-12 13:36
Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which
01-07 21:38
Moleculin Biotech Data From Phase Clinical Study Of WP1066 Demonstrates Anti-Tumor Immune Responses To Treat Pediatric Recurrent Malignant Brain Tumors
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac Cancer and Blood
2025-12-17 21:35
Moleculin Biotech Regains Nasdaq Compliance
The latest update is out from Moleculin Biotech ( ($MBRX) ). Moleculin Biotech,...
2025-12-17 06:55
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Moleculin Biotech Enters Inducement Offer Agreements
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, ...
2025-12-11 06:17
Moleculin announces exercise of warrants for $6.8M
Moleculin Biotech (MBRX) said on Wednesday that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain warrants to purchase up to an aggreg...
2025-12-10 22:07
